The MAP 2025 programme is now online!
MAP focuses on current and emerging approaches in precision oncology, highlights successes and challenges, and proposes potential solutions in clinical research and practice.
Learning objectives
- Share insights in the molecular characterisation and clonal evolution of cancer
- Understand emerging technologies for cancer profiling, including artificial intelligence
- Highlight mechanisms driving tumour expansion and metastatic dissemination of malignancy
- Learn about breakthroughs in our understanding of cancer epigenetic regulation and metabolic pathways
Accreditation
ESMO-MORA: The MAP Congress 2025 programme will be submitted for ESMO-MORA category 1. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.
Disclaimer
ESMO is a scientific and professional, non-political and non-religious organisation. ESMO will not accept responsibility for any comments or remarks made during any of our events by session chairs, invited speakers, presenters, members or any other contributor, formally or informally, which might cause offence or be perceived as being biased.
The experts invited by ESMO as abstract Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.
All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).
The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.